The 3rd Annual Tumor Myeloid-Directed Therapies Summit returns with over 75% new speakers to share insights across a range of myeloid targets, including CD40, CD39, LILRB2, CLEC-1 as well as CAR-M therapies. The one-stop shop continues to be your go-to forum to accelerate myeloid therapy progression by determining optimal combination strategy, optimize translational studies, discover novel targets, and guarantee patient safety. Connect with this up-and-coming community to reinvent targeting and harness the untapped potential of the myeloid.
Collaborate and learn from myeloid experts across industry and academia over 3 in-depth days of content, as they address the key bottlenecks limiting the efficacy and safety of these exciting treatments, including in vivo models, biomarkers of response, combination rationale, and myeloid biology to accelerate myeloid directed therapies.
To know more visit: https://ter.li/tm1bzy